白癜风发病机制研究热点解析

doi:10.3760/cma.j.issn.0412-4030.2019.09.001

摘要/Abstract

摘要： 【摘要】目前关于白癜风的发病机制研究除了以往备受关注的黑素细胞内在缺陷和T细胞介导的靶向黑素细胞的特异性免疫应答外，越来越多的研究关注黑素细胞内在损伤激活的固有免疫反应，以及角质形成细胞在白癜风皮肤免疫微环境中的关键调控作用。但仍有较多问题尚未解决，包括黑素细胞如何激活固有免疫、进而启动适应性免疫应答，以及角质形成细胞如何与T细胞交流调控皮肤免疫等。未来我们需要明确以上各方面如何协同促进白癜风黑素细胞损伤，进而开发针对性的治疗措施和药物。

关键词: 白癜风；黑素细胞；自身免疫；免疫, 先天

Abstract: 【Abstract】 While researches about pathogenesis of vitiligo have focused on intrinsic abnormalities of melanocytes and T cell?mediated specific immune response targeting melanocytes, the key role of innate immune response induced by intrinsic damage to melanocytes, and that of keratinocytes in the immune microenvironment in vitiligo skin lesions have become new hot spots recently. Many questions still remain unanswered, including how melanocytes trigger innate immune response and activate adaptive immune response, how keratinocytes and T cells alternately regulate skin immune responses, etc. In the next years, understanding how the above factors synergistically contribute to the damage to melanocytes in vitiligo will facilitate further development of new therapies and targeted drugs.

Key words: Vitiligo, Melanocytes, Autoimmunity, Immunity, innate

李春英李舒丽. 白癜风发病机制研究热点解析[J]. 中华皮肤科杂志, 2019, 52(9): 593-597.doi:10.3760/cma.j.issn.0412-4030.2019.09.001

Li Chunying, Li Shuli. Pathogenesis of vitiligo[J]. Chinese Journal of Dermatology, 2019, 52(9): 593-597.doi:10.3760/cma.j.issn.0412-4030.2019.09.001

参考文献 31

［1］	Denat L, Kadekaro AL, Marrot L, et al. Melanocytes as instigators and victims of oxidative stress［J］. J Invest Dermatol, 2014,134（6）:1512⁃1518. doi: 10.1038/jid.2014.65.
［2］	Yuksel EP, Aydin F, Senturk N, et al. Comparison of the efficacy of narrow band ultraviolet B and narrow band ultraviolet B plus topical catalase⁃superoxide dismutase treatment in vitiligo patients［J］. Eur J Dermatol, 2009,19（4）:341⁃344. doi: 10.1684/ejd.2009.0699.
［3］	He Y, Li S, Zhang W, et al. Dysregulated autophagy increased melanocyte sensitivity to H2O2⁃induced oxidative stress in vitiligo［J］. Sci Rep, 2017,7:42394. doi: 10.1038/srep42394.
［4］	Jian Z, Li K, Song P, et al. Impaired activation of the Nrf2⁃ARE signaling pathway undermines H2O2⁃induced oxidative stress response: a possible mechanism for melanocyte degeneration in vitiligo［J］. J Invest Dermatol, 2014,134（8）:2221⁃2230. doi: 10.1038/jid.2014.152.
［5］	Jian Z, Tang L, Yi X, et al. Aspirin induces Nrf2⁃mediated transcriptional activation of haem oxygenase⁃1 in protection of human melanocytes from H2O2⁃induced oxidative stress［J］. J Cell Mol Med, 2016,20（7）:1307⁃1318. doi: 10.1111/jcmm.12812.
［6］	Chang Y, Li S, Guo W, et al. Simvastatin protects human melanocytes from H2O2⁃induced oxidative stress by activating Nrf2［J］. J Invest Dermatol, 2017,137（6）:1286⁃1296. doi: 10. 1016/j.jid.2017.01.020.
［7］	Taieb A, Alomar A, Böhm M, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus［J］. Br J Dermatol, 2013,168（1）:5⁃19. doi: 10.1111/j.1365⁃2133.2012. 11197.x.
［8］	van den Boorn JG, Konijnenberg D, Dellemijn TA, et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients［J］. J Invest Dermatol, 2009,129（9）:2220⁃2232. doi: 10.1038/jid.2009.32.
［9］	Cheuk S, Schlums H, Gallais Sérézal I, et al. CD49a expression defines tissue⁃resident CD8+ T cells poised for cytotoxic function in human skin［J］. Immunity, 2017,46（2）:287⁃300. doi: 10.1016/j.immuni.2017.01.009.
［10］	Richmond JM, Strassner JP, Zapata L Jr, et al. Antibody blockade of IL⁃15 signaling has the potential to durably reverse vitiligo［J］. Sci Transl Med, 2018,10（450）. pii: eaam7710. doi: 10.1126/ scitranslmed.aam7710.
［11］	Rashighi M, Agarwal P, Richmond JM, et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo［J］. Sci Transl Med, 2014,6（223）:223ra23. doi: 10.1126/scitranslmed.3007811.
［12］	Wang XX, Wang QQ, Wu JQ, et al. Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo［J］. Br J Dermatol, 2016,174（6）:1318⁃1326. doi: 10.1111/bjd.14416.
［13］	Li S, Zhu G, Yang Y, et al. Oxidative stress drives CD8+ T⁃cell skin trafficking in patients with vitiligo through CXCL16 upregulation by activating the unfolded protein response in keratinocytes［J］. J Allergy Clin Immunol, 2017,140（1）:177⁃189.e9. doi: 10.1016/j.jaci.2016.10.013.
［14］	Rashighi M, Harris JE. Interfering with the IFN⁃γ/CXCL10 pathway to develop new targeted treatments for vitiligo［J］. Ann Transl Med, 2015,3（21）:343. doi: 10.3978/j.issn.2305⁃5839.2015. 11.36.
［15］	Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis⁃directed therapy［J］. JAMA Dermatol, 2015,151（10）:1110⁃1112. doi: 10.1001/jamadermatol.2015.1520.
［16］	Harris JE, Rashighi M, Nguyen N, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata （AA）［J］. J Am Acad Dermatol, 2016,74（2）:370⁃371. doi: 10.1016/j.jaad.2015.09.073.
［17］	Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib［J］. J Am Acad Dermatol, 2017,76（6）:1054⁃1060.e1. doi: 10.1016/j.jaad.2017. 02.049.
［18］	Joshipura D, Alomran A, Zancanaro P, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a 32⁃week open⁃label extension study with optional narrow⁃band ultraviolet B［J］. J Am Acad Dermatol, 2018,78（6）:1205⁃1207.e1. doi: 10. 1016/j.jaad.2018.02.023.
［19］	Liu LY, Strassner JP, Refat MA, et al. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure［J］. J Am Acad Dermatol, 2017,77（4）:675⁃682.e1. doi: 10.1016/j.jaad.2017.05.043.
［20］	Rezk AF, Kemp DM, El⁃Domyati M, et al. Misbalanced CXCL12 and CCL5 chemotactic signals in vitiligo onset and progression［J］. J Invest Dermatol, 2017,137（5）:1126⁃1134. doi: 10.1016/j.jid.2016.12.028.
［21］	Chatterjee S, Eby JM, Al⁃Khami AA, et al. A quantitative increase in regulatory T cells controls development of vitiligo［J］. J Invest Dermatol, 2014,134（5）:1285⁃1294. doi: 10.1038/jid.2013.540.
［22］	Eby JM, Kang HK, Tully ST, et al. CCL22 to activate treg migration and suppress depigmentation in vitiligo［J］. J Invest Dermatol, 2015,135（6）:1574⁃1580. doi: 10.1038/jid.2015.26.
［23］	Mosenson JA, Zloza A, Klarquist J, et al. HSP70i is a critical component of the immune response leading to vitiligo［J］. Pigment Cell Melanoma Res, 2012,25（1）:88⁃98. doi: 10.1111/j.1755⁃148X.2011.00916.x.
［24］	Mosenson JA, Zloza A, Nieland JD, et al. Mutant HSP70 reverses autoimmune depigmentation in vitiligo［J］. Sci Transl Med, 2013,5（174）:174ra28. doi: 10.1126/scitranslmed.3005127.
［25］	Henning SW, Fernandez MF, Mahon JP, et al. HSP70iQ435A⁃encoding dna repigments vitiligo lesions in sinclair swine［J］. J Invest Dermatol, 2018,138（12）:2531⁃2539. doi: 10.1016/j.jid.2018.06.186.
［26］	Zhang Y, Liu L, Jin L, et al. Oxidative stress⁃induced calreticulin expression and translocation: new insights into the destruction of melanocytes［J］. J Invest Dermatol, 2014,134（1）:183⁃191. doi: 10.1038/jid.2013.268.
［27］	Levandowski CB, Mailloux CM, Ferrara TM, et al. NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin⁃1β processing via the NLRP1 inflammasome［J］.Proc Natl Acad Sci U S A, 2013,110（8）:2952⁃2956. doi: 10.1073/pnas.1222808110.
［28］	Shi Q, Zhang W, Guo S, et al. Oxidative stress⁃induced overexpression of miR⁃25: the mechanism underlying the degeneration of melanocytes in vitiligo［J］. Cell Death Differ, 2016,23（3）:496⁃508. doi: 10.1038/cdd.2015.117.
［29］	Richmond JM, Bangari DS, Essien KI, et al. Keratinocyte⁃derived chemokines orchestrate T⁃cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease［J］. J Invest Dermatol, 2017,137（2）:350⁃358. doi: 10.1016/j.jid.2016.09.016.
［30］	Li S, Zhu G, Yang Y, et al. Oxidative stress⁃induced chemokine production mediates CD8（+） T cell skin trafficking in vitiligo［J］. J Investig Dermatol Symp Proc, 2015,17（1）:32⁃33. doi: 10.1038/jidsymp.2015.8.
［31］	Regazzetti C, Joly F, Marty C, et al. Transcriptional analysis of vitiligo skin reveals the alteration of WNT pathway: a promising target for repigmenting vitiligo patients［J］. J Invest Dermatol, 2015,135（12）:3105⁃3114. doi: 10.1038/jid.2015.335.

[1]	曹珂侯霄枭李昕 Christos C. Zouboulis 鞠强. 异维A酸对肽聚糖诱导的SZ95人皮脂腺细胞相关炎症基因表达的影响[J]. 中华皮肤科杂志, 2019, 52(4): 248-252.
[2]	王松挺张韡白娟乔建军. 先天性脂肿性头皮及脂肿性脱发一例[J]. 中华皮肤科杂志, 2018, 51(9): 682-683.
[3]	樊晓艳李慧汪佳杨丽. 先天性皮肤发育不全基因检测一例[J]. 中华皮肤科杂志, 2018, 51(6): 445-447.
[4]	王建波雷东春王伟霞李建国李雪莉李敏张守民李振鲁. 一对先天性大疱性鱼鳞病样红皮病双胞胎患者表型与角蛋白1基因突变研究[J]. 中华皮肤科杂志, 2018, 51(3): 186-188.
[5]	刘婷婷杨发灯林志淼汪慧君胡凌寒钟伟龙杨勇. 先天性常染色体隐性遗传性鱼鳞病两家系ABCA12基因突变分析[J]. 中华皮肤科杂志, 2018, 51(10): 737-740.
[6]	谢杰林尔艺杨斌顾有守. 先天性自愈性朗格汉斯组织细胞增生症一例[J]. 中华皮肤科杂志, 2017, 50(6): 458-458.
[7]	赵惠娟曾鑫闫慧敏郭独一雷鹏程路雪艳姜薇. 先天性常染色体隐性遗传性鱼鳞病一家系及PNPLA1基因突变分析[J]. 中华皮肤科杂志, 2017, 50(6): 408-411.
[8]	张晓辉邱丽倩陈丹青郭利芳阮黎明. 浙江省2013—2014年梅毒孕产妇不良妊娠结局分析[J]. 中华皮肤科杂志, 2016, 49(8): 558-562.
[9]	郭洪飞马学良. 先天性毛细血管扩张性大理石样皮肤一例[J]. 中华皮肤科杂志, 2010, 43(7): 503-503.
[10]	廖晖吴敏刘江波. 成人先天性无汗无痛症一例[J]. 中华皮肤科杂志, 2010, 43(6): 443-443.
[11]	汪澍. 一家族先天性厚甲二例[J]. 中华皮肤科杂志, 2009, 42(7): 480-480.
[12]	陈楠张锐利王震英宋亚丽李颂刘雯敏宋怀东潘春明. 基因诊断有汗性外胚层发育不良一家系[J]. 中华皮肤科杂志, 2009, 42(11): 745-747.
[13]	刘玉梅周欣田歆罗育武朱慧兰张锡宝. Glotz综合征一例[J]. 中华皮肤科杂志, 2009, 42(10): 726-726.
[14]	王建琴, 王汉平, 吴玉才, 谢健晋, 许志萍, 许剑荣, 孙广政, 方瑞华, 毛平, 曾仁山. 先天性角化不良的一个新的基因突变[J]. 中华皮肤科杂志, 2006, 39(6): 305-307.
[15]	周华, 潘鹏, 洪福昌, 陈钢, 杨帆, 林丽君, 蔡于茂. 胎传梅毒危险因素的病例对照研究[J]. 中华皮肤科杂志, 2006, 39(12): 681-684.